Board of Directors

Dr. Liang currently serves as Director of the company, responsible for overseeing all project development and company’s strategy and operations. In 2015, Dr. Liang co-founded iVIEW Therapeutics, Inc. and acquired global rights of Deda Pharmaceuticals’ all IP assets and also filed new IP applications based on new discoveries.

Dr. Bo Liang is a serial entrepreneur with over 15 years experience in drug discovery research, chemical and material sciences, biotechnology and materials venture and management. In 2006, Dr. Liang co-founded CLS Pharmaceuticals in New York City, where he invented a combination drug of Povidone Iodine and Dexamethasone, for the treatment of viral conjunctivitis. Within two years he has advanced the drug candidate into phase II trial, resulting in out-license to Foresight Biotherapeutics in 2008. From 2008-2010, Dr. Liang served as Executive Vice President, Pharmaceutical Development at Foresight to head the CMC development of the drug program for FST-100. After accomplishing phase II trials, the program was acquired by Shire Pharmaceuticals for $300m in 2015.

Dr. Liang was once a medicinal chemist at Pharmacopeia, Inc., where he made key contribution to alpha 2C program and led a new drug discovery program in treating respiratory diseases. Dr. Liang has published over 15 scientific articles and is the inventor on over 40 issued patents and patent applications. He was once Journal “Bioorganic and Medicinal Chemistry” invited reviewer. Besides his interest in topical drug development and innovative drug delivery technology, he was also CEO of Adesso Advanced Materials, which he co-founded in 2010 focusing on developing the world first recyclable resin materials in carbon fiber composite industry. Now Adesso has R&D operations and manufacturing base in Wuxi and Wuhu, China and EU business development center in Cambridge, UK. Adesso’s recyclable resin was first commercialized in carbon fiber composite sporting goods applications such as fishing rods and bicycle with target applications in lightweight automotive industry.

Dr. Liang obtained his BSc. in chemistry from Peking University in China in 1992, then was educated in US and got his PhD in synthetic organic chemistry from the University of Pennsylvania in 2001. He also obtained his MBA concentrating in entrepreneurship, and Finance from NYU Stern School of Business in 2008.

Dr. Baldwin serves as Co-founder and Director of the company. In 2015, Dr. Baldwin joined with Dr. Bo Liang to establish iVIEW Therapeutics, a company directed toward the development of novel formulations to overcome drug delivery issues.

Dr. Baldwin has spent 60 years in drug discovery and on novel technologies to increase the efficiency of the discovery process. While at Merck Research Laboratories, he made important contributions to the discovery and development of Trusopt and Cosopt, Edecrin, Aggrastat and Crixavan. His contributions in the area of Ophthalmology, are well known and were based on solving the vexing problem of arylsulfonamide’s bioavailability after topical administration.

After Merck, he became a founder and Chief Science Officer of Pharmacopeia Inc. where he pioneered the integration of combinatorial chemistry and high throughput screening into the drug discovery process. In 2001 he cofounded Vitae Pharmaceuticals where he was President and Chief Science Officer.

Dr. Baldwin was one of the first to recognize the drug discovery assets available in China. He was a founder of WuXi PharmaTech in Shanghai and served on the Board of Directors. More recently he became a Founder and Member of the Board for Hua Medicine in Shanghai and CarysBio in Foshan, China.

Dr. Baldwin obtained his PhD in Organic Chemistry from University of Minnesota. He has been recognized for his accomplishments by the American Chemical Society with the E.B. Hershberg Award and his nomination to the Medicinal Chemistry “Hall Of Fame”. He has also received the Philadelphia ACS Section Award and the 2012 PDDI Drug Discovery Award for Outstanding Contributions to Drug Discovery. Other Awards for outstanding achievement include those from the University of Minnesota, the University of Delaware and The Salesianum School. Dr. Baldwin has published over 150 scientific articles and is the inventor on over 250 issued U.S. patents. He has also served on the Advisory Council of the University of Minnesota’s Institute of Technology and on the Advisory Board for the Chemistry/Biochemistry Department University of Delaware. Dr. Baldwin has been elected to the Joseph Priestley Society of the Chemical Heritage Foundations and serves on Foundation’s Board of Overseers.

Dr. Tom Du is currently working as the Chief Consultant of Humphries Pharmaceutical Consulting, which is a global pharmaceutical consulting firm. Dr. Du is a physician and also a scientist. He graduated from Tianjin Medical University (TMU). He got his training in medicine at TMU and in pathology at McGill University, Montreal. Before joining the US Food and Drug Administration (FDA) as a reviewing officer in 1994, he had two years of fellowship training at Harvard University. When he worked at the FDA, Dr. Du worked in the Division of Pulmonary, Allergy and Rheumatology Products, and then worked in the Division of Oncology Products. He reviewed more than one hundred INDs and NDAs. Since leaving the FDA in 2000, he has held several important positions in the pharmaceutical industry. He worked as Senior Director, Clinical and Regulatory Affairs, Hutchison Whampoa Company based in Hong Kong. He served as Acting Managing Director, China operations, and then worked as Senior Director, Global Regulatory Affairs at Ingenix Pharmaceutical Services, an UnitedHealth Group Company.

Dr. Du has extensive experience in drug development and has held regulatory responsibilities in various therapeutic areas including oncology, pulmonary/allergy, gastrointestinal, and inflammatory, metabolic, and cardiovascular indications. He has been working as either project leader or project team member to help various American, European, and Asian drug makers develop their drug products and medical devices in the United States and China. Du’s team has participated in more than 100 IND, NDA, BLA, ANDA and PMA submissions in the United States during the past 15 years.

Dr. Du has also worked as a consultant for the American financial industry to evaluate the investment/business potentials of small or start-up pharmaceutical companies. He has served as a board member for two publicly listed biopharmaceutical companies in the North America. He worked as a consultant involved in the acquisitions of several pharmaceutical or medical device companies in the past ten years.

Dr. Du has published 22 articles on peer-reviewed scientific journals in the United States， Europe and China. Dr. Du was a member of FDA committees for Botanical Drug Products and Clinical Pathology. He has received several awards from the FDA and pharmaceutical industry. He is also a frequently requested speaker for major international forums. In recent years, he organized and/or participated in symposia on drug development and evaluation in China, Hong Kong, and the United States. Dr. Du has given several lectures to the Chinese CFDA officers in a training program held by the North Carolina State University from 2011 to 2015.

After he joined the pharmaceutical industry, he has helped more than 30 Chinese drug companies to submit ANDA or IND and initiate clinical trials for the development of herbal, biological, generic, and new chemical drugs in the United States. Dr. Du has been also working as a pharmaceutical expert in the investment communities of the United States and China. He has involved in various company’s fundraising and M&A during the past 10 years.